Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) generates a steady flow of news as a fully integrated, commercial-stage biotechnology company with both marketed products and a broad development pipeline. News coverage for Tonix often centers on its FDA-approved fibromyalgia treatment TONMYA, its acute migraine products Zembrace SymTouch and Tosymra, and updates on clinical and regulatory milestones across central nervous system, immunology, rare disease and infectious disease programs.
Investors following TNXP news can expect announcements on commercial launches, market access decisions, and distribution arrangements for TONMYA, as well as prescription trends and formulary placements for its migraine therapies. The company also regularly reports progress on TNX-102 SL in indications such as acute stress-related conditions and major depressive disorder, including IND clearances and the design of potentially pivotal Phase 2 studies.
Tonix’s immunology and infectious disease work contributes additional news items, including collaborations with academic centers like Massachusetts General Hospital for TNX-1500 in kidney transplantation, and development plans for TNX-4800, a monoclonal antibody designed for seasonal prevention of Lyme disease. Licensing transactions, such as the acquisition of TNX-4900 for chronic neuropathic pain from Rutgers University, and government-supported projects like the DTRA-backed antiviral TNX-4200, are also common themes in company press releases.
This TNXP news page aggregates company-issued updates and related coverage so readers can quickly review developments in Tonix’s commercial operations, clinical pipeline, financing activities, and strategic collaborations. For investors and observers tracking biotech catalysts, revisiting this page provides a concise way to monitor how Tonix’s programs and capital markets actions evolve over time.
Tonix Pharmaceuticals (Nasdaq: TNXP) reported post hoc Phase 3 analyses of TONMYA (cyclobenzaprine HCl sublingual tablets) presented March 9–10, 2026. Key findings include rapid pain relief as early as Day 2, Week 14 primary endpoint superiority (LS mean diff -0.65, p<0.001), and favorable pooled benefit-risk metrics (NNT 7; NNH 26; LHH 3.7).
The company noted TONMYA was generally well tolerated; oral cavity reactions were the most common adverse events.
Tonix Pharmaceuticals (Nasdaq: TNXP) presented Phase 3 data for TONMYA (cyclobenzaprine HCl sublingual tablets) at the 2026 AAPM PainConnect Annual Meeting. The 14-week RESILIENT trial (n=457) showed statistically significant mean daily pain reduction and higher 30% responder rates versus placebo. TONMYA received FDA approval in August 2025 and launched commercially in November 2025. The drug was generally well tolerated; most adverse events were mild, self-limited oral cavity reactions that rarely caused withdrawal.
Tonix Pharmaceuticals (NASDAQ: TNXP) announced publication of Phase 1 pharmacokinetic studies of TONMYA (TNX-102 SL), a sublingual cyclobenzaprine formulation FDA-approved Aug 15, 2025 and commercially launched Nov 2025. Two single-dose studies (n=24 and n=16) showed rapid transmucosal absorption, 154% relative bioavailability versus oral IR, ~3-minute absorption lag versus ~37 minutes, a 783% higher dose-normalized AUC in the first hour, dose proportionality, no food effect, and a norcyclobenzaprine elimination half-life of ~60 hours. Single doses were generally well tolerated; common AEs included oral hypoesthesia and abnormal taste.
Tonix Pharmaceuticals (Nasdaq: TNXP) will present a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets) at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting, March 5–8, 2026 in Salt Lake City.
Poster #50, titled "Treatment with TNX-102 SL Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia," will be presented March 6, 2026 at 4:55 PM ET by Errol Gould, PhD. A copy of the presentation will be available on the company presentations webpage.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective at market open on March 3, 2026, under the existing ticker TNXP.
The company says the uplisting reflects compliance with higher financial and governance standards and may enhance visibility, liquidity and institutional access. Tonix is a commercial-stage biotech with recently approved TONMYA™ for fibromyalgia and marketed acute migraine products, plus multiple investigational CNS and immunology programs.
Tonix Pharmaceuticals (Nasdaq: TNXP) said management will participate in two investor conferences in March 2026: a company presentation at TD Cowen on March 4, 2026 and 1x1 meetings at Barclays from March 10–12, 2026.
A live webcast of the March 4 presentation will be available on the company's Investor Events page, with a replay accessible for 90 days. The company highlighted its recently approved flagship product TONMYA and a CNS and immunology pipeline including TNX-2900, TNX-4800, and TNX-1500.
Tonix Pharmaceuticals (Nasdaq: TNXP) presented positive Phase 3 RESILIENT data for TONMYA (sublingual cyclobenzaprine HCl) at the 2026 Non-Opioid Pain Therapeutics Summit on January 29, 2026.
In a 14-week, 456-participant randomized double-blind trial, TONMYA produced a statistically significant reduction in weekly average pain at Week 14 (p<0.0001; effect size 0.38) and significant improvements in sleep, fatigue, and Fibromyalgia Impact Questionnaire domains. TONMYA was approved by the FDA on August 15, 2025, and was generally well tolerated with low weight and blood pressure effects.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman, M.D. will present and host investor meetings at two January 2026 conferences in San Francisco: Sachs Associates 9th Annual Neuroscience Innovation Forum on Jan 11, 2026 (presentation 11:55 a.m. PT; panel 1:15 p.m. PT) and Biotech Showcase on Jan 13, 2026 (presentation 11:00 a.m. PT). A replay will be posted on the company website and investor meetings can be requested via sebastian.gomez@astrpartners.com.
Company highlights: marketed products TONMYA for fibromyalgia, Zembrace SymTouch and Tosymra for acute migraine, plus a CNS, immunology, rare disease and infectious disease pipeline including TNX-102 SL, TNX-1500, TNX-2900, TNX-801, TNX-4800 and TNX-4200 (DTRA contract up to $34M).
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a registered direct offering with Point72 to purchase 615,025 shares of common stock or pre-funded warrants at $16.26 per share (or $16.259 per pre-funded warrant), generating approximately $20.0 million gross proceeds before fees. The closing is expected on or about December 30, 2025, subject to customary conditions. Net proceeds are intended to fund commercialization of marketed products, development of the product pipeline, and general working capital. TD Cowen is sole placement agent; A.G.P./Alliance Global Partners is financial advisor. The offering is on an effective Form S-3 registration.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced program updates for TNX-4800, a long-acting human monoclonal antibody targeting OspA for seasonal Lyme disease prevention.
The company plans an FDA meeting in 2026 to explore Phase 2/3 options including a controlled human infection model (CHIM) and an adaptive Phase 2/3 field study. Tonix expects GMP investigational product to be available for clinical testing in early 2027. The company estimates ~70 million people in U.S. Lyme-endemic areas could potentially benefit. The release notes there are no currently marketed FDA-approved vaccines or prophylactics for Lyme disease and describes TNX-4800 as providing near-immediate immunity after one subcutaneous dose for seasonal protection.